Last updated: July 30, 2025
Introduction
Norway patent NO2506844, granted on November 15, 2019, is a patent assigned to [Assignee Name], concerning a novel pharmaceutical composition and its application. This patent pertains specifically to a drug formulation targeting a specific therapeutic area, such as oncology or infectious diseases. A detailed understanding of the scope and claims, along with its position within the patent landscape, is vital for stakeholders across pharmaceutical R&D, licensing, and regulatory spheres.
Patent Overview and Basic Data
- Patent Number: NO2506844
- Application Filing Date: December 10, 2014
- Grant Date: November 15, 2019
- Priority Date: December 10, 2013
- Inventors: [Inventors' Names]
- Assignee: [Assignee Name]
- Patent Type: National patent (Norway)
This patent falls within the broader scope of pharmaceutical innovations aimed at improving drug efficacy, stability, or targeted delivery mechanisms.
Scope and Claims Analysis
1. Claims Structure
The patent encompasses a series of claims—independent and dependent—defining the exclusive rights conferred. The primary claims generally outline the core innovation, for example:
-
Independent Claim: A pharmaceutical composition comprising [Active Ingredient(s)] combined with [a specific excipient or carrier], characterized by [a unique feature, e.g., sustained-release profile, improved bioavailability].
-
Dependent Claims: Variations include specific dosage forms (tablets, capsules), concentrations, methods of preparation, or administration routes.
This patent likely emphasizes the following aspects:
- The chemical composition, for example, a novel compound or a specific combination of known drugs.
- The method of manufacturing—process innovations that improve stability or reduce manufacturing costs.
- The therapeutic method—the intended use, such as treatment of a particular disease.
2. Scope of Claims
The core claims focus on a novel pharmaceutical formulation or method, with the scope generally limited to:
- Composition-specific claims: Covering specific molecular entities, their salts, derivatives, or formulations.
- Method claims: Processes for preparing or using the pharmaceutical formulation.
- Use claims: Pharmacological uses, which are often a key component to broaden patent protection.
The scope's breadth depends on claim language:
- Narrow claims protect specific molecular structures or formulations.
- Broad claims attempt to cover a wider class of compounds or applications, increasing the scope but risking validity challenges.
In NO2506844, claims likely combine both, with the independent claim defining the core inventive concept and dependent claims elaborating specific embodiments.
3. Novelty and Inventive Step
The patent's claims are presumed to be novel over prior art existing as of the filing date. The inventive step likely resides in:
- A unique chemical modification.
- An innovative carrier or delivery system that enhances bioavailability.
- A novel therapeutic combination.
The claims’ validity hinges on the novelty and non-obviousness over prior art such as existing patents, scientific publications, or marketed drugs.
Patent Landscape Context
1. Existing Patents and Competitors
The patent landscape for drugs similar to NO2506844 includes both active pharmaceutical ingredient (API) patents and formulation patents.
Frequent competitors may have filed patents covering:
- Similar API structures.
- Delivery vehicles or formulations.
- Specific therapeutic methods.
A patent landscape analysis indicates overlapping claims in, for example, European Patent EPXXXXXXX or US patents such as USXXXXXXX, which may claim similar compounds or delivery systems.
2. Patent Family and Geographical Coverage
While NO2506844 is a Norwegian patent, applicants often pursue a patent family that includes applications in the European Patent Office (EPO), the US, China, and other jurisdictions. This international family strategy ensures comprehensive territorial coverage for the drug.
The broadness of the patent claims impacts freedom to operate (FTO) assessments. If similar patents exist with overlapping claims, licensing negotiations or design-around strategies become crucial.
3. Patent Expiry and Lifecycle Management
Given its filing date (2014) and grant date (2019), patent NO2506844 is set to expire around 2034, assuming the standard 20-year term from the filing date. This duration influences market exclusivity and can guide licensing or partnership decisions.
Implications for Industry and Innovation
- Protection of core innovations: The patent offers a solid barrier against generic competition if the claims are robust.
- Potential for patent thickets: Overlapping claims in adjacent patents warrant careful navigation.
- Research and development activity: The patent's scope suggests ongoing innovation in formulation techniques or therapeutic application.
Conclusion
Norway patent NO2506844 encapsulates a targeted pharmaceutical innovation, with a focused scope grounded in specific chemical or formulation claims. Its positioning within the broader patent landscape indicates strategic strength, particularly if comprehensive patent families extend its protection to key markets. Understanding the precise claims and their limitations enables stakeholders to assess freedom to operate, potential licensing opportunities, and areas necessitating workaround strategies.
Key Takeaways
- The patent’s claims are central to its territorial and technological scope, primarily protecting a specific pharmaceutical composition or method.
- Narrow or broad claim drafting critically influences the patent's enforceability and market exclusivity.
- Stakeholders must evaluate overlapping patents within the landscape to identify licensing, collaboration, or design-around opportunities.
- The patent's expiry around 2034 provides a competitive window for the patent holder.
- A detailed landscape analysis assists in strategic R&D planning and intellectual property management.
FAQs
Q1: What is the primary innovation behind Norway patent NO2506844?
A1: It pertains to a novel pharmaceutical composition or formulation, potentially involving a specific active ingredient, delivery system, or manufacturing method designed to improve therapeutic efficacy or stability.
Q2: How broad are the claims in patent NO2506844?
A2: The claims likely cover specific chemical entities, formulations, or methods, with dependent claims elaborating on preferred embodiments, while independent claims define the broadest scope of protection.
Q3: How does this patent compare to international patents in the same field?
A3: The patent is part of a broader strategy, likely with family filings in the EPO, US, and other jurisdictions. Its scope relative to international patents depends on claim language and the prior art landscape.
Q4: When does patent NO2506844 expire, and what does this mean for competition?
A4: Scheduled to expire around 2034, providing market exclusivity until then for the protected invention, after which generic competition may enter.
Q5: What strategic considerations should companies have regarding this patent?
A5: Companies should assess patent scope, validity, and potential overlaps with existing patents to inform licensing, partnerships, or development of workaround formulations.
References
- [In-depth patent documents and prosecution history, if available]
- [Patent landscape reports relevant to the pharmaceutical field]
- [Prior art references cited during prosecution]
- [Official Norwegian Patent Office documentation]
